Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Net Cash Flow (2019 - 2025)

Historic Net Cash Flow for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $6.9 million.

  • Pliant Therapeutics' Net Cash Flow rose 99766.23% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 3972.67%. This contributed to the annual value of $8.0 million for FY2024, which is 7436.84% down from last year.
  • Latest data reveals that Pliant Therapeutics reported Net Cash Flow of $6.9 million as of Q3 2025, which was up 99766.23% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' Net Cash Flow registered a high of $68.8 million during Q1 2023, and its lowest value of -$47.6 million during Q2 2023.
  • Over the past 5 years, Pliant Therapeutics' median Net Cash Flow value was -$63000.0 (recorded in 2021), while the average stood at $2.3 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first tumbled by 3024920.63% in 2022, then skyrocketed by 99766.23% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Net Cash Flow stood at $6.4 million in 2021, then crashed by 269.93% to -$10.9 million in 2022, then skyrocketed by 164.37% to $7.0 million in 2023, then plummeted by 219.75% to -$8.4 million in 2024, then surged by 182.01% to $6.9 million in 2025.
  • Its Net Cash Flow was $6.9 million in Q3 2025, compared to -$5.1 million in Q2 2025 and $20.7 million in Q1 2025.